GSK LSE Week ended 07 Aug 2026

Weekly Investor Report

GSK plc · Healthcare · Drug Manufacturers - General

Open interactive chart View report data
Latest close 1,960 GBP
1.5% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -1.6% below the Trend Line and sits at 67.7% of its 52-week range. The latest completed week returned 1.5%, after a -0.1% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 59/100.

Setup score 50 out of 100
Latest Close 1,960 GBP 7 Aug 2026
1W Return 1.5% latest completed week
4W Return -0.1% short-term follow-through
12W Return 5.3% quarterly tape
Trend Breadth 63.5% 33 of 52 weeks active
Volume Ratio 1.1x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
  • Next-week expectancy is positive at 57.09% based on similar historical setup states.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.5% Latest completed week; four-week move -0.1%. Indicator stack 35/53 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 57.09% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 59/100 8 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -1.6% below the Trend Line and sits at 67.7% of its 52-week range. The latest completed week returned 1.5%, after a -0.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2912-week average 0.41

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership8/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.29Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -0.1% over four weeks, 5.3% over 12 weeks, and 40.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W1.5%
4W-0.1%
12W5.3%
26W-10.8%
52W40.5%
Active trend streak0 weeks
Active weeks in one year33
Trend breadth63.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.16Latest activity-pressure read.
Pressure change76.0%Four-week change in activity pressure.
Leadership-2.19Latest relative-leadership reading.
RS change-178.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 91% Model confidence 85%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength59/100Blend of value, momentum, and quality. Underlying universe rank 42; rank 1 is best.
Value15/100Relative valuation strength. Underlying universe rank 86; rank 1 is best.
Quality99/100Profitability and accounting quality. Underlying universe rank 2; rank 1 is best.
Momentum93/100Medium-term price momentum. Underlying universe rank 8; rank 1 is best.
Growth89/100Revenue and earnings growth. Underlying universe rank 12; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
13.5x
Price divided by trailing earnings.
Price / sales
2.4x
Market value relative to trailing revenue.
EV / EBITDA
9.0x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
5.0%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
72.7%
Gross profit retained from each unit of revenue.
Operating margin
25.7%
Operating profit retained from revenue.
Free-cash-flow margin
14.5%
Free cash flow generated from revenue.
Return on invested capital
18.9%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
4.1%
Latest one-year revenue growth.
EPS growth
125.8%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
33.1%
Latest one-year free-cash-flow growth.
Piotroski F-score
9/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
3.4%
Cash dividends relative to market value.
Buyback yield
1.8%
Net share repurchases relative to market value.
Shareholder yield
5.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
1.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment59/100

Weighted news tone is positive across 8 relevant articles.

3 positive · 5 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-14.1%Distance below the 52-week high.
13-week volatility2.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+5.0%Week of 27 Mar.
Worst week-7.4%Week of 6 Mar.
Latest week+1.5%Week of 7 Aug.

Shape of recent returns

Strong gains2
Modest gains11
Flat weeks0
Modest losses10
Sharp losses3
Recent vol2.1%13-week weekly-return volatility.
Base vol3.9%52-week weekly-return volatility.
Up/down split28/23Count of positive and negative weeks in the 52-week window.
Average skew3.1% / -2.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

IndustryGB Drug Manufacturers - General
4-week rank1 / 2
Group average-3.4%
Trend breadth0.0%
Trend0.0%active weekly trend signals
MD0.0%positive activity pressure
RS0.0%positive relative leadership

Four-week leaders

GSK · LSE-0.1%AZN · LSE-6.7%
08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape48/100

Trend, activity pressure, participation, and risk combine to a 48/100 tape read.

 Indicator analysis26/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 8/12.

Activity pressure 0.29; No reversal markers Next-Week ExpectancyPositive 57.09%

Next-week expectancy is positive with a 57.09% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors66/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 27 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment59/100

Weighted news tone is positive across 8 relevant articles.

GSK plc (GSK) president reports acquisition of notional ADS in savings plan Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20261,960 GBP1.5%1,992 GBP1,615 GBP-0.16-2.1928.2MOff
31 Jul 20261,932 GBP0.6%1,989 GBP1,611 GBP-0.30-3.0754.2MOff
24 Jul 20261,920 GBP0.2%1,986 GBP1,607 GBP-0.47-2.2547.7MOff
17 Jul 20261,916 GBP-2.3%1,982 GBP1,604 GBP-0.56-0.8835.8MOff
10 Jul 20261,962 GBP-2.7%1,979 GBP1,600 GBP-0.692.7835.5MOff
3 Jul 20262,015 GBP1.6%1,975 GBP1,596 GBP-0.834.112.5MOff
26 Jun 20261,983 GBP3.0%1,968 GBP1,592 GBP-0.994.4513.8MOff
19 Jun 20261,926 GBP-2.9%1,961 GBP1,588 GBP-1.113.1615.1MOff
12 Jun 20261,984 GBP2.4%1,957 GBP1,585 GBP-1.185.485.5MOff
5 Jun 20261,938 GBP3.0%1,950 GBP1,581 GBP-1.244.286.4MOff
29 May 20261,882 GBP-1.7%1,944 GBP1,577 GBP-1.251.0138.4MOff
22 May 20261,915 GBP2.8%1,941 GBP1,574 GBP-1.232.3522.1MOff
15 May 20261,862 GBP1.1%1,931 GBP1,570 GBP-1.122.4042.4MOff
8 May 20261,843 GBP-3.1%1,923 GBP1,568 GBP-0.941.1937.4MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context